US FDA approves Lupkynis (voclosporin)

More great news for people with lupus! The U.S. Food and Drug Administration (FDA) has approved Lupkynis™ (voclosporin) to treat lupus nephritis (lupus-related kidney disease) in adults when used in combination with a background immunosuppressive therapy regimen. Lupkynis is the second new therapy authorized to treat this potentially life-threatening complication of lupus. Developed by Aurinia…

US FDA approve Benlysta

GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA The U.S. Food and Drug Administration (FDA) in late December 2020 approved Benlysta® to treat lupus nephritis (lupus-related kidney disease) in adults. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Another milestone, this new…